Applied Capital Lease Obligations from 2010 to 2024
| APLT Stock | USD 8.57 1.64 16.06% |
Capital Lease Obligations | First Reported 2019-12-31 | Previous Quarter 215 K | Current Value 2 M | Quarterly Volatility 589.3 K |
Check Applied Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Applied Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.4 M, Interest Income of 1.1 M or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 22.59, Dividend Yield of 0.0 or Days Sales Outstanding of 8.33. Applied financial statements analysis is a perfect complement when working with Applied Therapeutics Valuation or Volatility modules.
Applied | Capital Lease Obligations |
Latest Applied Therapeutics' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Applied Therapeutics over the last few years. Applied Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Applied Therapeutics asset purchases. For example, Applied Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Applied Therapeutics control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Applied Therapeutics' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Applied Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Applied Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 1,684,177 | |
| Geometric Mean | 1,519,448 | |
| Coefficient Of Variation | 35.61 | |
| Mean Deviation | 480,274 | |
| Median | 2,039,000 | |
| Standard Deviation | 599,689 | |
| Sample Variance | 359.6B | |
| Range | 1.6M | |
| R-Value | (0.80) | |
| Mean Square Error | 138.9B | |
| R-Squared | 0.64 | |
| Significance | 0.0003 | |
| Slope | (107,380) | |
| Total Sum of Squares | 5T |
Applied Capital Lease Obligations History
About Applied Therapeutics Financial Statements
Applied Therapeutics shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Applied Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Applied Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Applied Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 467 K | 443.6 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Applied Stock Analysis
When running Applied Therapeutics' price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.